CBPartners Leads Two Days of Debate About Value and Access at the 2013 Payers’ Forum Europe

Share Article

Monica Martin de Bustamante led a team of CBPartners consultants who provided advisory support and case studies to a diverse group of European pricing and reimbursement authorities and industry executives in Berlin.

News Image
One of the core principles of effective payer engagement by the pharmaceutical industry includes understanding the budgetary decision-makers’ motivations and their capacity to act.

CBPartners, one of the world’s leading authorities on strategic issues related to healthcare, is proud to announce the firm’s involvement with the 2013 Payers’ Forum Europe, a meeting coordinated in conjunction with eyeforpharma.

The meeting’s key theme was to form more collaborative relationships among pharmaceutical payers and the industry. The meeting explored a variety of related topics, including management within an environment of austerity, HTA harmonisation, and payer-perspectives on strategic planning for access in Germany and England.

Ms. Monica Martin de Bustamante, Managing Director of CBPartners, moderated a panel exploring methods for success with clinical commissioning groups, the new budgetary decision-makers throughout the United Kingdom. “One of the core principles of effective payer engagement by the pharmaceutical industry includes understanding the budgetary decision-makers’ motivations and their capacity to act,” Ms. Bustamante explains. “Quite often, we find that pharmaceutical manufacturers can complicate a rather simple value story by including extraneous data and statements that simply muddy the waters.”

The CBPartners team also ran a successful session educating the attendees about recent examples of pharmaceutical manufacturers who effectively communicate the value of their products, thereby yielding positive reimbursement decisions. Dr. Rachel Beckerman, Principal of Value Demonstration, also supported the session’s case-based approach, adding, “HTA agencies are raising the standards expected to receive positive scores and reimbursement decisions. The evidence-based requirements are at an all-time high; the good news, however, is that HTA agencies are open to early-consultations so that their views can be incorporated within pivotal trial designs.”

The content from the clinical trial design session will be made available through CBPartners, and can be found at http://www.cbpartners.com/thoughtleadership/conferences.html. If you would like more information about how CBPartners can help, please contact them at info(at)cbpartners(dot)com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

To find out more, please contact info(at)cbpartners(dot)com, visit http://www.cbpartners.com, or follow CBPartners on Twitter:http://www.twitter.com/CBPartners.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cyrus Chowdhury
+1 (347) 221-9536
Email >
Visit website